Researchers from the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute describe a new method that dramatically simplifies an arduous experimental process in early drug discovery.
The Licensed IP, which represents Prism’s material asset, is currently undergoing patent review, and is actively being deployed in connection with the cultivation of psilocybin-containing mushrooms at ...
YOKOHAMA, Japan, June 13, 2013 /PRNewswire/ -- PRISM Pharma Co., Ltd., a drug discovery company focused on developing small molecule technologies that modulate protein-protein interactions, today ...
Cell lines have long served as tools for oncology drug discovery 5. Their track record in predicting efficacy in patients, however, has been mixed. Cell line models often have been chosen more for ...
CAMBRIDGE, MA, February 29, 2016 - In a paper published in Nature Biotechnology, researchers from the Broad Institute of MIT and Harvard and the Dana-Farber Cancer Institute describe a new method that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results